Key Summary Points {#FPar1}
==================

Shock is an acute circulatory failure leading to inadequate oxygen delivery to the body cells.Its treatment is based on fluid optimization and vasopressor drugs. The drug of choice is norepinephrine.In some cases, norepinephrine is not efficacious, and other vasoactive drugs like corticosteroids, vasopressin, and angiotensin II should be administered. Some authors also suggest the use of methylene blue.Methylene blue has demonstrated efficacy if used very early, but the existing data are still too few.This review article on the knowns and unknowns of methylene blue has tried to make clear whether the published data may be enough to draw conclusions useful to physicians.

Introduction {#Sec1}
============

Shock is defined as an acute syndrome of circulatory failure leading to inadequate oxygen delivery to the cells \[[@CR1]\]. A number of different pathophysiological mechanisms may cause shock, including cardiogenic factors, obstruction, distributive factors (anaphylaxis or sepsis), and hypovolemia. In intensive care patients, the most common type of shock is septic (62%), followed by cardiogenic (16%) and hypovolemic shock (16%). Other types of obstructive and vasodilatory shock are relatively less frequent \[[@CR1]\].

Treatment of distributive shock, the most frequent, is largely dependent on managing hypotension, ensuring adequate systemic and microcirculatory flow, and tissue oxygenation \[[@CR2]\]. To improve arterial pressure, and therefore organ perfusion, intravenous vasopressors are often employed. Among others, norepinephrine is recommended as first choice to obtain mean arterial pressure (MAP) at greater than 60--65 mmHg \[[@CR2]\]. This hemodynamic goal may require large doses of the drug. At high dosages, it may be responsible for added risk for adverse events such as dysrhythmias, peripheral ischemia, and increased myocardial oxygen consumption \[[@CR3]\]. Other potential side effects include hypercoagulability, immunomodulation, and gastrointestinal peristalsis alterations, and extravasation \[[@CR3]\]. Moreover, several patients are identified as "non-responders" to first-line norepinephrine treatment \[[@CR2]\].

Because of the risks associated with catecholamine vasopressors, interest has grown in using catecholamine-sparing agents in order to achieve hemodynamic target with lower catecholamine doses. Although definitions for catecholamine-sparing agents vary, it is agreed that those medicines should reduce the norepinephrine dose by 50% or more for 4 h without any reduction from the patient's baseline MAP \[[@CR4]\]. Well-known adjuvant agents used for catecholamine-sparing effects in shock include vasopressin, corticosteroids, whose effect on microcirculation has been demonstrated for about half century \[[@CR5]\], and angiotensin II \[[@CR4]\].

Methylene blue (MB) represents an additional option useful to provide a catecholamine-sparing effect, but its use is controversial. This review aims to summarize current evidence for MB as adjuvant therapy in critically ill patients with distributive shock. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Shock: Pathophysiology and Treatment {#Sec2}
====================================

Pathophysiology {#Sec3}
---------------

The definition of shock has evolved over centuries. In the eighteenth century, "shock" indicated a sudden deterioration of a patient's condition after a major trauma. While the term "shock" has taken on many meanings, the current emphasis is on imbalance of tissue perfusion in relation to cellular oxygen demand. Whatever the cause might be, hemodynamic shock is characterized by a decrease in tissue perfusion associated with cellular and metabolic abnormalities. Therefore, the goal of shock resuscitation is to improve tissue perfusion by restoring perfusion pressure of vital organs, ensuring an adequate oxygen delivery (DO~2~), and, when possible, improving microvascular alterations \[[@CR6]\]. Hypovolemic shock is a condition of inadequate organ perfusion caused by loss of intravascular volume, resulting in decreased preload, stroke volume (SV), and cardiac output (CO) with a compensatory increase in systemic vascular resistance (SVR) in order to maintain perfusion. Distributive shock is characterized by a decrease of SVR and by an abnormal distribution of microvascular blood flow in the presence of normal or increased CO (Table [1](#Tab1){ref-type="table"}). In septic shock, the response to pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPS) generates a combination of vasodilatation and increased capillary permeability. Capillary leak, coupled with greater vessel capacitance mediated by vasoplegia, may result in absolute or more commonly relative hypovolemia \[[@CR7]\].Table 1Types of circulatory shock and their clinical featuresType of shockMAPCODO~2~CVPSVRClinical examplesHypovolemic↓→↓↓↓↑Hemorrhage burnsDistributive↓↑↑↓↓SIRS/Sepsis anaphylaxisObstructive↓↓↓↑↑→Pulmonary embolism tension PNXCardiogenic↓→↓↓↑↑Myocardial infarction arrhythmia*MAP* mean arterial pressure, *CO* cardiac output, *CVP* central venous pressure, *SVR* systemic vascular resistance, *DO*~*2*~ delivery of oxygen, *SIRS* systemic inflammatory response syndrome, *PNX* pneumothorax, ↑ increased, ↓ decreased, → no change

Treatment {#Sec4}
---------

Shock has been traditionally treated with fluids as a first step in order to increase preload and therefore SV and CO. However, because either too much or too little fluid can have a negative impact on patient outcomes, fluid administration must be carefully tailored to each patient. The "salvage, optimization, stabilization, de-escalation" (SOSD) mnemonic rule has been proposed as a general guide to fluid resuscitation \[[@CR8]\]. It suggests that in the initial salvage phase fluid should be administered generously, but once hemodynamic monitoring is available, fluid administration should be optimized by determining the patient's real fluid requirement. Dynamic tests of fluid responsiveness such as pulse pressure or stroke volume variation together with fluid challenge technique are the most frequently used to assess ongoing fluid requirements \[[@CR9]\]. Once a patient has been stabilized, efforts should start to eliminate excess of fluids.

However, fluid administration alone is often insufficient to increase perfusion pressure. Vasopressors correct the underlying deficit in SVR, thus restoring MAP, perfusion pressure, and ideally tissue perfusion pressure. Autoregulatory threshold should be maintained to ensure perfusion to vital organs. The optimal MAP target probably lies between 65 and 75 mmHg in most patient with sepsis \[[@CR10]\]. Therefore, in this kind of shock, it seems reasonable to administer vasopressors in order to obtain the optimal blood pressure target (i.e., MAP \> 65 mmHg).

Norepinephrine, a potent α agonist and less potent β agonist, is the vasopressor of choice in septic shock \[[@CR11]\]. It increases smooth muscle intracellular calcium concentration and mediates vasoconstriction with some positive inotropic activity, increasing ventricular contractility. However, several patients are identified as "non-responders" to first-line norepinephrine treatment, i.e., when a pre-defined maximum dose was reached or when further increase of the first vasopressor was supposedly ineffective \[[@CR2]\]. In norepinephrine-refractory patients, vasopressin or epinephrine may be added. Epinephrine has more β~1~ agonism than norepinephrine, but its use is burdened by increased risk of splanchnic vasoconstriction, tachyarrhythmias, and hyperlactatemia. Vasopressors may in turn magnify sepsis-induced myocardial dysfunction, so inotropic agents (e.g., dobutamine) are commonly added to increase cardiac output. However, in recent years several concerns are arising regarding their use, since all these agents may cause direct organ damage and have multiple harmful biological effects on the immune system and metabolic and coagulation pathways (i.e., hyperglycemia; cardiac, cerebral, splanchnic, renal, and digital ischemia; hyperlactatemia) that can negatively affect patients' outcomes \[[@CR6]\]. Moreover, all these pharmacological approaches act on macrocirculation variables, such as MAP, systemic vascular resistance index (SVRI), and CO, but an increased CO does not always meet the perfusion requirements of organs.

This condition (the so-called loss of hemodynamic coherence) \[[@CR12]\] is most frequently found in the early phase of sepsis when a lack of microcirculatory recruitment is observed despite successful macrocirculatory resuscitation. The microcirculation can be considered as a vital organ whose function ensures the adequate DO~2~ to the various tissue cells \[[@CR13]\]. It is a complex network of resistance and exchange vessels, where perfusion is dependent on numerous factors. The entire organ comprises endothelial cells, a layer of glycocalyx covering the endothelial cells and smooth cells. Vascular smooth muscle cells (VSMC) in the tunica media regulate vascular tone, depending on intracellular calcium (Ca^2+^) concentration. Relaxation of the VSMC is driven by a decrease in cytosolic Ca^2+^, due to uptake of Ca^2+^ by the sarcoplasmic reticulum and expulsion of potassium (K^+^) or Ca^2+^ (via K^+^ channels and Ca^2+^-ATPase pumps) into the extracellular space, resulting in cellular hyperpolarization and vasodilation. The endothelium regulates blood flow in response to local stimuli, resulting in upstream signaling to VSMC to dilate. The glycocalyx layer forms an important barrier and transduction system that can be disrupted under conditions of inflammation and cardiovascular disease. A large number of cellular components complete the picture: platelets, coagulation factors, cytokines, and chemokines. In sepsis, all the components of the microcirculation listed above are affected, causing a severe dysfunction in its regulatory function and resulting in a regional mismatch of oxygen supply and demand \[[@CR13]\].

Nitric Oxide {#Sec5}
============

In various conditions of distributive shock such as sepsis and anaphylaxis, as well as other vasoplegic conditions such as in cardiac surgery, increased levels of nitric oxide (NO) and activation of soluble guanylyl cyclase (sGC) are well documented and are responsible for the mismatch between macro- and microcirculation. NO has many functions, such as serving as a messenger molecule, regulating gene transcription and mRNA translation, as well as regulation of vascular tone \[[@CR14]\]. NO diffuses freely from the endothelium into the neighboring VSMC and bloodstream causing vasodilation, inhibition of VSMC proliferation, platelet activation, and leukocyte adhesion \[[@CR15]\]. Moreover, NO may cause blood vessel relaxation by activating the sGC, leading to activation of the cyclic guanosine monophosphate (cGMP)-dependent protein kinases (PKGs) \[[@CR7]\].

In mammals, NO can be generated by three different isoforms of the enzyme NO synthase (NOS): neuronal NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2), and endothelial NOS (eNOS, NOS3) \[[@CR13]\]. All isoforms of NOS utilize[l]{.smallcaps}-arginine as a substrate along with oxygen and reduced nicotinamide adenine dinucleotide phosphate as co-substrates. In addition, all isoforms of NOS bind calmodulin and calcium; activated calmodulin is important for the regulation of eNOS and nNOS activity. nNOS is found primarily in the brain and spinal cord where it modulates learning, neurogenesis, memory, and regulates blood pressure. Very recent evidence suggests a pivotal role of abnormal NO signaling and oxidative stress mediated by neuroinflammation in the pathogenesis of neurodegenerative diseases \[[@CR14], [@CR16]\]. eNOS exists primarily in endothelial cells, but also occurs in other cell types including platelets and cardiac myocytes. The physiologic functions of eNOS include inhibition of platelet aggregation and adhesion and inhibition of leukocyte aggregation. The primary role of eNOS appears to be regulation of cardiovascular functions such as blood pressure. Bradykinin, thrombin, and histamine increase NO production and vasodilation by activating eNOS. In addition, inflammatory cytokines and PAMPs such as lipopolysaccharide (LPS) induce the synthesis of the third calcium-independent iNOS isoform. This results in an increase in NO of two to three orders of magnitude \[[@CR14], [@CR15]\]. iNOS was first identified in macrophages, but other cells such as hepatocytes, enterocytes, Paneth cells, or VSMC are sources of iNOS as well \[[@CR15]\]. Excessive NO synthesis and induction of iNOS have been implicated in further promotion of vasodilation and hyporeactivity to pressor agents during sepsis \[[@CR15]\]. The NO-mediated hypotension leads to severe hypoxia in peripheral vital organs, resulting in progressive organ failure. NO may also directly contribute to tissue and organ injury by its direct, peroxynitrite-mediated cytotoxic effects \[[@CR15]\]. Interestingly during the late phase of shock there is an impairment of the biosynthesis of NO by eNOS in vascular endothelium, the constitutive form being downregulated as the inducible form is expressed \[[@CR17]\].

Activation of sGC is an important signaling pathway of NO, resulting in the production of cGMP. sGC catalyze conversion of the purine nucleoside guanosine-5′-triphosphate to cGMP in response to various messengers such as peptide ligands, calcium influx, and NO. sGC activation in VSMC produces vasorelaxation and inhibits smooth muscle proliferation. In VSMC, the activation of the eNOS--sGC pathway is essential in order to increase permeability and proliferation \[[@CR18]\].

Redundant activation of the NO--cGMP pathway has been associated with distributive shock such as sepsis and anaphylaxis \[[@CR14], [@CR19]\]. However, NO may exert protective effects through its capacity to counteract oxidative stress \[[@CR16]\], extinguish apoptosis, prevent platelet and leukocyte adhesion, induce anti-inflammatory activity, and kill pathogens \[[@CR14], [@CR17]\]. This dual personality of NO can help to explain why unselective NOS inhibitors fail to provide clinical benefits in patients with sepsis \[[@CR14]\]. Therefore, nowadays clinical research is focusing on the so-called selective iNOS inhibitors and on NO scavengers, with the aim to further target the therapy on microcirculation impairment, prevent toxicity and/or shock caused by excessive NO, while preserving some essential NO activities in the proximity of its area of production.

Methylene Blue {#Sec6}
==============

As a result of binding to the iron heme moiety of sGC and blocking sGC action in vascular smooth muscle, MB decreases the levels of cGMP and alleviates its vasorelaxant effect (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR20]\]. MB also has the ability to scavenge NO as well as to selectively inhibit iNOs \[[@CR21]\]. When given intravenously, MB concentrations peak at 30 min with an onset of action of 30--60 min. It has a relatively large volume of distribution (255 ± 58 L) and is highly protein bound (94%). Excretion occurs via the bile, fecal, and renal routes \[[@CR20]--[@CR22]\]. Intravenous administration typically has a terminal plasma half-life of 5--6 h, and continuous infusions may be beneficial after the initial bolus for up to 48--72 h. As a result of the short-term effects of MB, a number of studies also evaluated prolonged infusions of MB with doses of 0.25--2 mg/kg/h, up to 120 h \[[@CR20]--[@CR22]\].Fig. 1Scheme of NO production and possible action of methylene blue. IL-1 interleukin-1, IL-6 interleukin-6, TNFα tumor necrosis factor alpha, NO nitric oxide, iNOS inducible nitric oxide synthase, cNOS constitutive nitric oxide synthase, MB methylene blue, sGC soluble guanylyl cyclase, cGMP cyclic guanosine monophosphate, GTP guanosine triphosphate, ANP atrial natriuretic peptide

Perhaps, the most common use of MB is as a dye in clinical investigations of the gastrointestinal or urinary systems. MB has also been used in oncology for sentinel lymph node detection. A less common but well-established use of MB is the treatment of methemoglobinemia complicating topical benzocaine use, where MB hastens the conversion of methemoglobin to hemoglobin. MB has also been utilized in patients with congenital methemoglobinemia, priapism, neonatal hypotension, or as an antimalarial agent \[[@CR20], [@CR21]\]. In vasodilatory shock, a therapeutic bolus of 1--2 mg/kg is commonly administered over 10--20 min, or up to 1 h. The appealing mechanism of action of MB (i.e., selectively blocking sGC as well as inhibiting iNOS) explains why it is regarded not as a pure vasoconstrictor but instead as a selective agent on the microcirculation dysregulation in cases of NO upregulation. Growing evidence is emerging regarding its use in several vasoplegic conditions such as sepsis, anaphylaxis, hemodialysis, cardiac surgery, and liver transplantation or end-stage liver disease \[[@CR23]--[@CR29]\].

Methylene Blue and Septic Shock {#Sec7}
-------------------------------

Two randomized controlled trials evaluated the use of MB in treating hypotension secondary to septic shock \[[@CR27], [@CR28]\]. In both studies, as well as in observational ones and case reports \[[@CR29]--[@CR35]\], MB was able to cause a statistically significant increase of MAP (see Table [2](#Tab2){ref-type="table"} for details of included studies). MB led to significant increases in systemic vascular resistance \[[@CR29], [@CR31], [@CR32]\]. A recent meta-analysis shows that MB blue could significantly increase MAP in patients with refractory hypotension caused by vascular paralysis during the course of vasodilatory shock and decrease the lactate levels \[[@CR36]\]. Administration of MB was able to facilitate the weaning of catecholamine vasopressors as well \[[@CR28], [@CR31], [@CR35]\].Table 2Characteristic of included studiesStudyStudy design*N*Patient populationVasopressorsDoseOutcomesSide effectsSeptic shock Memis 2002 \[[@CR27]\]Prospective, randomized, double-blind, placebo-controlled study30Severe sepsis0.5 mg/kg/h over 6 hMAP was significantly increased from baseline immediately after infusion, no difference at 24 h; mortality rate was similar in both groupsBlue coloration of urine, increased methemoglobin concentration Kirov 2001 \[[@CR28]\]Prospective, open-label, randomized, placebo-controlled20Severe sepsis and/or septic shockNE \> 0.05 μg/kg/min and EPI \> 0.05 μg/kg/min to maintain MAP 70--90 mmHg2 mg/kg follow by a stepwise infusion until 0.5 mg/kg/h for 6 hMAP increased significantly immediately after infusion; requirement of vasopressors reduced significantly; no difference in in-hospital mortality rateResolving blue coloration of urine and skin Weingartner 1999 \[[@CR29]\]Prospective, open-label, non-randomized10Severe septic shockNE 0.7 μg/kg/min4 mg/kg for 4 hSignificant increase of MAP and SVRIPaO~2~/FiO~2~ ratio significantly decreased at 40 min, remained lower during the infusion period Donati 2002 \[[@CR30]\]Prospective, open-label, non-randomizedUnresponsive septic shockNE and/or DOPA (1.5--3 μg/kg/min)Immediate increase of MAP and SVRISlight increase in plasma osmolarity Brown 1996 \[[@CR31]\]Case report1Septic shockDOPA 10 μg/kg/min and NE 15 μg/min100 mg bolus followed by 17 mg/h for 44 hIncrease of MAP reduced vasopressor, aliveResolving blue coloration of urine and skin Park 2005 \[[@CR32]\]Prospective, open-label, non-randomized20Refractory septic shockDOPA \> 20 μg/kg/min1 mg/kg in 15 minSignificant increase of MAP and SVRI till 2 h; 65% mortality Andresen 1998 \[[@CR33]\]Prospective, open-label, non-randomized10Severe septic shockNE \> 0.2 μg/kg/min, EPI \> 0.1 μg/kg/min1 mg/kg for 15 minSignificant increase of MAP and SVRI Gachot 1995 \[[@CR34]\]Prospective, open-label, non-randomized6Severe septic shockNE 4 μg/kg/h and/or EPI 2 μg/kg/h3 mg/kg in 10 minSignificant increase of MAP and SVRI; all but one diedPaO~2~/FiO~2~ ratio significantly decreased Dumbarton 2011 \[[@CR35]\]Case report1Septic shockNE 1 μg/g/kg/min, VASO 0.04 U/min, EPI 1 μg/kg/min to maintain MAP \> 65 mmHg100 mg bolus and continuous infusion at 0.5 mg/kg/h till 120 hIncrease in blood pressure, allowing for a decrease in NE and EPI; aliveBlue/green discoloration of the skin and mucosa, particularly noticeable in his extremitiesOther types of shock Porizka 2020 \[[@CR40]\]Retrospective study20Refractory distributive shock: 9 patients (45%) responded positively to MB administration and 11 patients (55%) were non-respondersNE \> 0.5 μg/kg/min and CI \> 2.4 L/min/m^2^1.3 ± 0.5 vs. 1.3 ± 0.4 mg/kg respectivelyLower NE requirements in 12 post infusion, lower mortality, and lower hypoxic state in responders Manjii 2017 \[[@CR41]\]Case report1Undifferentiated shockNE 0.9 μg/kg/min and 0.04 unit/min of VASO to maintain MAP \> 60 mmHg2 mg/kg for a total dose of 190 mg onceNE was halved in 2 h, vasopressors weaned in 15 h; alive Oliveira Neto 2003 \[[@CR42]\]Case report3Anaphylactic shock induced by radiocontrast injection during coronary angiographyRefractory hypotension despite DOPA1.5--2 mg/kgIncrease of MAP, all aliveTransient nodal cardiac rhythm, chest pain Fisher 2014 \[[@CR43]\]Case report1Refractory distributive shock following a mixed drug poisoning (carbamazepine, quetiapine, fluoxetine, valproate, oxazepam)NE 100 μg/min, VASO 0.06 units/min, metaraminol 133 μg/min DOPA 5 μg/kg/min1.5 mg/kg and continuous infusion (1.5 mg/kg/h for 12 h, then 0.75 mg/kg/h for 12 h)Improvement in hemodynamic parameters and weaning ofvasopressors in the following hours; alive Graham 2015 \[[@CR44]\]Case report1Vasodilatory shock following overdose of metformin and gliclazideNE 1.7 mg/kg/min and VASO at 0.06 units/min to maintain MAP of 50--55 mmHg2 mg/kg followed by an infusion at 0.25 mg/kg/h for approximately 20 hOver the following 24 h, the vasopressors were slowly weaned; aliveBlue discoloration of urine Aggarwal 2013 \[[@CR45]\]Case report1Vasodilatory shock following calcium channel blocker and a β-blocker overdoseNE 1 μg/kg/min and DOPA 20 μg/kg/min VASO 0.8 U/min1 mg/kg over a 10 min period and then for 10 hMAP stabilization in 8 h, vasopressor de-escalation; aliveTransient bluish discoloration of the urine, tears, saliva, and skin Laes 2015 \[[@CR46]\]Case report1Vasodilatory shock following ingestion of atenolol, amlodipine, and valsartanNE 0.1 μg/kg/min, EPI titrated to 0.1 μg/kg/min, and VASO 0.04 units/min to maintain MAP 60 mmHg2 mg/kg IV over 30 min and after infusion of 0.75 mg/kg/hSVRI increased and MAP unchanged; vasopressor requirements decreased within 2 h; aliveNone*N* number of patients, *MAP* mean arterial pressure, *NE* norepinephrine, *DOPA* dopamine, *VASO* vasopressin, *SVRI* systemic vascular resistance index, *EPI* epinephrine, *CI* cardiac index, *PaO*~*2*~ oxygen arterial pressure, *FiO*~*2*~ fraction of inspired oxygen

However, the MB doses administered and concomitant vasopressor titration parameters were inconsistent among all studies. The reduction of catecholamines ranges from 2 up to 24 h after MB infusion. Moreover, several studies tested MB use in cases of refractory vasodilatory shock with no response to conventional treatment, and therefore started it late in treatment. This may not be the correct approach, since a possible "window of opportunity" for the MB's effectiveness in sepsis has been proposed \[[@CR37]\]. In the first 8 h, there is increased iNOS activity and sGC upregulation. In the second 8 h, there is an absence of sGC expression and a downregulation of iNOS. In the third 8-h window, there is an upregulation of sGC and iNOS. Therefore, MB use as a last rescue therapeutic option goes against the aforementioned concepts, and it is possible that MB does not act (second window) or acts too late (third window) when the circulatory shock is metabolically irreversible, presenting high lactate levels and intractable metabolic acidosis. Perhaps it is more useful to consider MB not as a late rescue treatment but as an adjuvant drug to be used early (first window) \[[@CR38]\].

Although MB may improve hemodynamics by increasing MAP, a corresponding mortality benefit was not seen overall. The meta-analysis by Belletti et al. \[[@CR39]\], focusing on the effect of non-adrenergic vasopressors in patients with or at risk for vasodilatory shock (including MB), found that none of the drugs was associated with significant reduction in mortality when analyzed independently. A lack of overall mortality benefit may be attributed to the short-acting effects of MB. As a result of the shorter duration of action, prolonged or continuous infusions may be necessary in patients with persistent hypotension. A recent retrospective analysis of 20 critically ill patients with refractory shock gives new insight into the action of MB \[[@CR40]\]. Patients were defined as responders with positive hemodynamic response to MB administration (10% decrease of norepinephrine dose) and non-responders. There were 9 (45%) responders and 11 (55%) non-responders to administration of a single bolus of MB. Those who responded had significantly improved survival compared to those with no hemodynamic response. Also, non-responders were in a more profound state of tissue hypoxia documented by significant metabolic acidosis and higher lactate levels compared to responders. The authors concluded that a patient's responsiveness to MB may depend on the degree of actual tissue hypoxia and anaerobic metabolism, thus confirming its beneficial effect early in the course of shock state before the profound ischemic tissue changes develop and vasoplegic syndrome progresses to its refractory phase. The mortality benefit seen in MB responders may likely be related to the lesser degree of tissue hypoxia rather than to the sole effect of MB and the decrease of vasopressor requirements.

Methylene Blue and Other Types of Shock {#Sec8}
---------------------------------------

In addition to use in septic shock, MB has also been studied in anaphylactic and drug-induced shock or undifferentiated shock \[[@CR41]--[@CR46]\]. Medications involved include contrast medium, antidiabetics, antidepressants, and antihypertensives (e.g., amlodipine, atenolol, and valsartan). For both indications, literature support was limited to case reports and case series. However, in the majority of cases, benefit was seen in terms of patient survival and reduction in catecholamine vasopressor. Again, clinical inference may be limited as a result of observational study designs, the unclear kind of shock (anaphylaxis, immune-mediated, or non-immune-mediated), the limit of publication bias (i.e., the tendency to publish only positive results), as well as the fact that results may be affected by potential confounders such as concomitant use of corticosteroids and the natural progression of shock.

Safety {#Sec9}
------

MB was generally well tolerated in all studies: the main adverse effects reported were blue discoloration of the skin and more commonly of the urine. This effect is relatively harmless and reverses in a few days upon discontinuation of the medication. Other adverse effects known to occur with administration of MB include flushing, dizziness, nausea, and chest and limb pain.

Even though this topic is still discussed, in small studies on patients in septic shock, MB was found to lead to worsening arterial oxygenation and reduced ratios of arterial oxygen tension to fraction of inspired oxygen (P/F), because of inhibition of hypoxic pulmonary vasoconstriction and impaired alveolocapillary gas exchange in the lung \[[@CR29], [@CR34]\]. To avoid these risks, it may be prudent to avoid use of higher doses in patients with acute lung injury and acute respiratory distress syndrome (ARDS), where the pulmonary elasticity is highly compromised \[[@CR47]\]. MB may also lead to mesenteric vasoconstriction and compromised blood flow, in particular at high doses (up to 4 mg/kg). Continuous peripheral infusion of MB for prolonged duration may lead to local cutaneous necrosis and administration (bolus and/or infusion) can also cause artificially low pulse oximetry readings because of the blue coloration. This is because its spectral absorption is similar to that of the difference between oxyhemoglobin and reduced hemoglobin.

Toxic manifestations of MB are dose related. At doses greater than 4 mg/kg, MB may catalyze oxidation of the ferrous ion in hemoglobin and increase methemoglobin. Hemolysis, nausea and vomiting, chest pain, and hypertension have been reported for doses more than 7 mg/kg. At high doses (\> 20 mg/kg), MB can cause severe intravascular hemolysis, hyperbilirubinemia, and death.

Moreover, MB inhibits monoamine oxidase A, which is an enzyme responsible for breaking down serotonin in the brain. Serotonin syndrome has been reported in those taking antidepressant medications. Serotonin syndrome is a life-threatening condition that causes altered mental status, altered neuromuscular excitability, and autonomic instability.

In addition, MB inhibits cytochrome P450 (CYP) isozymes and may affect hepatic medication metabolism. Typically, medications with a narrow therapeutic index metabolized by the same cytochrome will be most affected. MB is metabolized by the liver and excreted by the kidneys. Patients with hepatic or renal dysfunction are at risk of toxicities and potential drug interactions.

The use of MB is contraindicated during pregnancy because of the increased expression of NO in the placenta and subsequent risk of fetal hypoxia following MB administration. Lastly, MB is contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency and may cause hemolytic anemia owing to a decreased ability to reduce MB into its metabolites \[[@CR10], [@CR21], [@CR48]\].

Conclusions {#Sec10}
===========

The role of MB as a catecholamine-sparing agent in the management of vasodilatory shock is under debate. The mechanism of action for NO inhibition in the management of vasodilatory shock appears promising, even though the limited data with inconsistent findings poses several doubts on its use in clinical practice. Owing to the benefits in terms of increasing MAP, increasing SVR, and reducing catecholamine vasopressor requirements, MB at a dose of 1--2 mg/kg IV bolus may be an option for use in patients with sepsis who remain hypotensive despite adequate fluid replacement and receiving multiple vasoactive agents \[[@CR21], [@CR22]\]. Continuous infusions, up to 0.25--0.50 mg/kg/h, may be used in persistent hypotension owing to its short duration of action. It is also reasonable to avoid higher doses in patients with acute lung injury and ARDS because of the deleterious effects seen on pulmonary function. Recent evidence suggests that earlier use of MB (in the first 8 h of sepsis) could be more effective on NO action. Experience with the use of MB in anaphylactic shock is limited to case reports and it is unclear whether the reactions were anaphylaxis or anaphylactic shock, immune-mediated, or non-immune-mediated.

Routine use of MB is not strongly recommended at the moment, but it may be appropriate as add-on therapy for its catecholamine-sparing effects in certain vasoplegic scenarios. Further studies are needed to clarify which dosing strategies, which patients, and when MB could find a right place in therapy.

Limitations of the Study {#Sec11}
------------------------

This narrative review has explored and synthesized most of the published material regarding the clinical use of MB in the treatment of patients in shock. Better indications on its usefulness would derive from a systematic review with meta-analysis of the data. At the moment, this does not seem to be possible, considering the low number of randomized controlled trials of good quality studying the use of MB in standardized conditions. Hence, a narrative review has been preferred instead in order to stimulate the scientific discussion.
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